The Influence of the 34C>T Variant in the AMPD1 Gene Ischemic Tolerance
Primary Purpose
AMPD, Ischemic Tolerance
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
systemic administration of 99mTc-HYNIC-Annexin A5
10 minutes of ischemic handgripping
Sponsored by

About this trial
This is an interventional diagnostic trial for AMPD
Eligibility Criteria
Inclusion Criteria: male 18-40 years healthy AMPD1 34C>T variant (heterozygous) or matched control Exclusion Criteria: cardiovascular / pulmonary disease diabetes / hypertension
Sites / Locations
Outcomes
Primary Outcome Measures
99mTc-Annexin A5 targeting
Secondary Outcome Measures
Full Information
NCT ID
NCT00319059
First Posted
April 27, 2006
Last Updated
April 21, 2016
Sponsor
Radboud University Medical Center
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development
1. Study Identification
Unique Protocol Identification Number
NCT00319059
Brief Title
The Influence of the 34C>T Variant in the AMPD1 Gene Ischemic Tolerance
Official Title
The Influence of the 34C>T Variant in the AMPD1 Gene on Individual Susceptibility for Ischemia-reperfusion.
Study Type
Interventional
2. Study Status
Record Verification Date
April 2016
Overall Recruitment Status
Completed
Study Start Date
March 2006 (undefined)
Primary Completion Date
April 2006 (Actual)
Study Completion Date
April 2006 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Radboud University Medical Center
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development
4. Oversight
5. Study Description
Brief Summary
Previous epidemiological studies have shown that in cardiovascular patients, the 34C>T variant in the gene encoding for the enzyme Adenosine Mono Phosphate Deaminase (AMPD1) is associated with prolonged survival.
The 34 C>T variant encodes a severely truncated, metabolically inactive protein. We hypothesize that during ischemia, in these patients AMP in preferentially converted into adenosine instead of IMP. Adenosine receptor stimulation, in turn, will increase resistance to ischemia-reperfusion in the myocardial tissue.
To test this hypothesis, 7 male healthy volunteers heterozygous for the 34C>T variant will be selected from 100 healthy volunteers, which we have previously genotyped. These subjects will be compared with 7 matched control subjects. Individual ischemic tolerance will be assessed in the thenar muscle using 99mTc-Annexin A5 scintigraphy.
Briefly, the circulation of the nondominant forearm will be interrupted for 10 minutes by inflation of an upperarm cuff to 200mmHg en concomitantly, the subjects will perform isometric rhythmic handgripping until exhaustion. Immediately upon reperfusion, 400 MBq of 99mTc-Annexin A5 will be administered intravenously. Finally, 1 and 4 hours post-injection, scintigrapghi imaging of both hand will be performed. Targeting of annexin A5 will be expressed as percentage difference between the experimental and control hand.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
AMPD, Ischemic Tolerance
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Single
Allocation
Non-Randomized
Enrollment
14 (false)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
systemic administration of 99mTc-HYNIC-Annexin A5
Intervention Type
Behavioral
Intervention Name(s)
10 minutes of ischemic handgripping
Primary Outcome Measure Information:
Title
99mTc-Annexin A5 targeting
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
male
18-40 years
healthy
AMPD1 34C>T variant (heterozygous) or matched control
Exclusion Criteria:
cardiovascular / pulmonary disease
diabetes / hypertension
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gerard Rongen, MD, PhD
Organizational Affiliation
Radboud University Medical Center
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
The Influence of the 34C>T Variant in the AMPD1 Gene Ischemic Tolerance
We'll reach out to this number within 24 hrs